Martin Hirsch

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, 65 Landsdowne St, Room 419, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 49:3483-5. 2005
  2. doi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
    Martin S Hirsch
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 47:266-85. 2008
  3. doi request reprint Initiating therapy: when to start, what to use
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Infect Dis 197:S252-60. 2008
  4. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
  5. ncbi request reprint Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Clin Infect Dis 37:1119-24. 2003
  6. pmc Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts 02114, USA
    Antimicrob Agents Chemother 46:1336-9. 2002
  7. ncbi request reprint Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection
    Cecile L Tremblay
    Massachusetts General Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    AIDS 17:1086-9. 2003
  8. pmc Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 47:3644-6. 2003
  9. pmc Antiretroviral therapy in the clinic
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne St, Cambridge, MA 02139, USA
    J Virol 84:5458-64. 2010
  10. ncbi request reprint Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 42:426-34. 2006

Research Grants

  1. MULTIDISCIPLINARY AIDS TRAINING GRANT
    Martin Hirsch; Fiscal Year: 2007

Detail Information

Publications28

  1. pmc TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, 65 Landsdowne St, Room 419, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 49:3483-5. 2005
    ..Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted...
  2. doi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
    Martin S Hirsch
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 47:266-85. 2008
    ..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important...
  3. doi request reprint Initiating therapy: when to start, what to use
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Infect Dis 197:S252-60. 2008
    ..Some new antiretroviral drugs under study, particularly integrase inhibitors, may prove useful in treatment-naive patients...
  4. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
    ..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation...
  5. ncbi request reprint Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Clin Infect Dis 37:1119-24. 2003
    ..Hyperbilirubinemia (experienced by 31% of subjects), nausea (17%), abdominal pain (14%), and nephrolithiasis (13%) were the most common drug-related adverse events during the extension...
  6. pmc Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts 02114, USA
    Antimicrob Agents Chemother 46:1336-9. 2002
    ..These findings suggest that SCH-C may be a useful anti-HIV drug in combination regimens and that a combination of chemokine coreceptor/fusion inhibitors may be useful in the treatment of multidrug-resistant viruses...
  7. ncbi request reprint Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection
    Cecile L Tremblay
    Massachusetts General Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    AIDS 17:1086-9. 2003
    ..Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted...
  8. pmc Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro
    Cecile L Tremblay
    Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 47:3644-6. 2003
    ..53 to 1.06 at 95% inhibitory concentrations. These studies suggest that a combination of T-20 and DAPD might be useful in the treatment of antiretroviral drug-experienced patients...
  9. pmc Antiretroviral therapy in the clinic
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne St, Cambridge, MA 02139, USA
    J Virol 84:5458-64. 2010
    ....
  10. ncbi request reprint Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 42:426-34. 2006
    ..To assess the effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy (ART)...
  11. ncbi request reprint Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus
    Rajesh T Gandhi
    Infectious Diseases Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 37:1693-8. 2003
    ..Moreover, it suggests that, despite initially impaired viral fitness, a transmitted HIV-1 isolate with multiple drug resistance mutations can evolve to develop increased RC and significant pathogenicity...
  12. ncbi request reprint Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection
    Robert W Shafer
    Stanford University Medical Center, Stanford, Calif, USA
    N Engl J Med 349:2304-15. 2003
    ..It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens...
  13. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
    ..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
  14. pmc Monitoring HIV treatment in developing countries
    Serena P Koenig
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    BMJ 332:602-4. 2006
  15. ncbi request reprint Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  16. doi request reprint Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
    ....
  17. ncbi request reprint Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  18. ncbi request reprint HIV drug resistance--a chink in the armor
    Martin S Hirsch
    N Engl J Med 347:438-9. 2002
  19. ncbi request reprint Entecavir surprise
    Martin S Hirsch
    N Engl J Med 356:2641-3. 2007
  20. ncbi request reprint Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study
    Alison A Motsinger
    Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Pharmacogenet Genomics 16:837-45. 2006
    ..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms...
  21. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  22. ncbi request reprint Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel
    Martin S Hirsch
    Top HIV Med 11:150-4. 2003
    ..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing...
  23. ncbi request reprint TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro
    Cecile L Tremblay
    Antivir Ther 10:967-8. 2005
  24. ncbi request reprint Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
    David W Haas
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 192:1931-42. 2005
    ..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment...
  25. pmc Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
    ..There were no significant differences in efavirenz pharmacokinetics...
  26. ncbi request reprint Justice in Libya? Let scientific evidence prevail
    Martin S Hirsch
    J Infect Dis 195:467-8. 2007
  27. ncbi request reprint Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy
    Adriana Weinberg
    University of Colorado School of Medicine, Denver, 80262, USA
    J Infect Dis 193:488-93. 2006
    ..CMV viremia did not appear to boost CMV-specific immunity. ELISPOT assays may be used to identify HIV-infected patients who might benefit from anti-CMV prophylactic interventions...
  28. ncbi request reprint A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re
    Michael J Borucki
    University of Texas Health Center, Tyler, TX, USA
    Antiviral Res 64:103-11. 2004
    ....

Research Grants6

  1. MULTIDISCIPLINARY AIDS TRAINING GRANT
    Martin Hirsch; Fiscal Year: 2007
    ..The faculty collaborates with one another on AIDS research and will collaborate in directing this training program. ..